产品
编 号：F156529
分子式：C66H80N12O17
分子量：1313.41
分子式：C66H80N12O17
分子量：1313.41
产品类型
规格
价格
是否有货
结构图
CAS No: 1421446-02-7
产品详情
生物活性：
Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity.
体内研究：
Pasireotide (160 mg/kg/mouth; s.c. for 4 months) diaspartate significantly decreases the serum insulin, increases serum glucose, reduces the tumor size and increases apoptosis in Pdx1-Cre.Pasireotide (2-50 μg/kg; s.c. twice daily for 42 days) diaspartate exerts the antinociceptive and antiinflammatory actions via the SSTR2 receptor in a mouse model of immune-mediated arthritis.Animal Model:12 month-old conditional Men1 knockout mice with insulinoma
Dosage:160 mg/kg/mouth
Administration:S.c. every month for 4 months
Result:Decreased the serum insulin from 1.060 μg/L to 0.3653 μg/L and increased the serum glucose from 4.246 mM to 7.122 mM.Significantly reduced the tumor size and increased apoptosis.
体外研究：
Pasireotide diaspartate exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/Pasireotide (diaspartate) 相关抗体:
Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity.
体内研究：
Pasireotide (160 mg/kg/mouth; s.c. for 4 months) diaspartate significantly decreases the serum insulin, increases serum glucose, reduces the tumor size and increases apoptosis in Pdx1-Cre.Pasireotide (2-50 μg/kg; s.c. twice daily for 42 days) diaspartate exerts the antinociceptive and antiinflammatory actions via the SSTR2 receptor in a mouse model of immune-mediated arthritis.Animal Model:12 month-old conditional Men1 knockout mice with insulinoma
Dosage:160 mg/kg/mouth
Administration:S.c. every month for 4 months
Result:Decreased the serum insulin from 1.060 μg/L to 0.3653 μg/L and increased the serum glucose from 4.246 mM to 7.122 mM.Significantly reduced the tumor size and increased apoptosis.
体外研究：
Pasireotide diaspartate exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/Pasireotide (diaspartate) 相关抗体:
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备